Evidence map›Paper›PMID 36154354›Full record

ArticleDrug delivery2022

Cuprous oxide-based nanocrystals with combined chemo/chemodynamic therapy to increase tumor drug sensitivity by reducing mitochondria-derived adenosine-triphosphate.

Haoran He, Jiaming Wu, Min Liang, Yao Xiao, Xuejian Wei, Yuqin Cao, Zhiheng Chen, Tian Lin, Miaosheng Ye

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug delivery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Haoran HeThe Second People's Hospital of Nanhai District, Guangdong Provincial People's Hosptial's Nanhai Hospital, Foshan, Guangdong Province, China.
Jiaming WuDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang Province, China.
Min LiangDepartment of Oncology, Innovation Centre for Advanced Interdisciplinary Medicine, Guangzhou Key Laboratory of Enhanced Recovery after Abdominal Surgery, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong Province, China.
Yao XiaoDepartment of Oncology, Innovation Centre for Advanced Interdisciplinary Medicine, Guangzhou Key Laboratory of Enhanced Recovery after Abdominal Surgery, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong Province, China.
Xuejian WeiThe Second People's Hospital of Nanhai District, Guangdong Provincial People's Hosptial's Nanhai Hospital, Foshan, Guangdong Province, China.
Yuqin CaoThe Second People's Hospital of Nanhai District, Guangdong Provincial People's Hosptial's Nanhai Hospital, Foshan, Guangdong Province, China.
Zhiheng ChenDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang Province, China.
Tian LinNanfang Hospital, The First School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong Province, China.
Miaosheng YeThe Second People's Hospital of Nanhai District, Guangdong Provincial People's Hosptial's Nanhai Hospital, Foshan, Guangdong Province, China.
Guangzhou Medical University · CNFirst Hospital of Jiaxing · CNJiaxing University · CNSouthern Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastrointestinal (GI) tumor is a serious disease with high mortality rates and morbidity rates worldwide. Chemotherapy is a key treatment for GI, however, systematic side effects and inevitable drug resistance complicate the situation. In the process of therapy, P-glycoprotein (P-gp) could remove chemotherapy drugs from cells, thus causing multi-drug resistance. Chemodynamic therapy (CDT) utilizing Fenton chemistry has been used for cancer therapy, along with various combination therapies. The reactive oxygen species produced by CDT could inhibit P-gp's efflux pump function, which reduce chemoagents excretion and reverse drug resistance. In the present study, we developed novel nanocrystals (Cu

Indexed as

NanoparticlesNeoplasmsAdenosineAdenosine TriphosphateAnimalsATP Binding Cassette Transporter, Subfamily BCell Line, TumorCopperDrug Resistance, MultipleMiceMitochondriaPolyphosphatesReactive Oxygen SpeciesAdenosineAdenosine TriphosphateATP Binding Cassette Transporter, Subfamily BCoppercuprous oxidePolyphosphatesReactive Oxygen Speciestriphosphoric acidchemodynamic therapy (CDT)Cuprous oxide (Cu2O)drug resistancemitochondria damageP-glycoprotein (P-gp)

Identifiers

PMID36154354
PMCPMC9518603
OpenAlexW4297154340

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.